Ceftaroline in CNS and Ocular Infections: a Case Series

Overview

Journal JAC Antimicrob Resist

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2024 Jun 18

PMID 38887612

Authors

Emily A Siegrist

Joseph Sassine

Affiliations

Soon will be listed here.

Abstract

Background: There are limited data describing outcomes of patients treated with ceftaroline for infections with CNS or ocular involvement.

Objectives: To describe outcomes of patients treated with ceftaroline for methicillin-resistant staphylococcal infections involving the CNS or eye.

Patients And Methods: This was a retrospective review of 10 patients at an academic medical centre who received ceftaroline for CNS or ocular infections.

Results: All patients were treated with ceftaroline as part of a combination for salvage therapy. Four patients died, whereas six patients experienced clinical cure. Only one experienced microbiological recurrence.

Conclusions: These preliminary data suggest that ceftaroline may be an option for salvage therapy of severe staphylococcal infections when used in combination.

References

Sakoulas G, Nonejuie P, Kullar R, Pogliano J, Rybak M, Nizet V . Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37. Antimicrob Agents Chemother. 2015; 59(4):2428-31. PMC: 4356754. DOI: 10.1128/AAC.04965-14. View

Riser M, Bland C, Rudisill C, Bookstaver P . Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann Pharmacother. 2010; 44(11):1832-5. DOI: 10.1345/aph.1P307. View

Kuriakose S, Rabbat M, Gallagher J . Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother. 2014; 70(3):953-4. DOI: 10.1093/jac/dku464. View

Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K . Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2019; 63(5). PMC: 6496065. DOI: 10.1128/AAC.02483-18. View

Holmes N, Owen Robinson J, van Hal S, Munckhof W, Athan E, Korman T . Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia. BMC Infect Dis. 2018; 18(1):107. PMC: 5838938. DOI: 10.1186/s12879-018-3011-2. View

Britt R, Evoy K, Lee G, Reveles K, Sorensen K, Jones X . Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System. Drugs. 2017; 77(12):1345-1351. PMC: 5553123. DOI: 10.1007/s40265-017-0785-2. View

Pani A, Colombo F, Agnelli F, Frantellizzi V, Baratta F, Pastori D . Off-label use of ceftaroline fosamil: A systematic review. Int J Antimicrob Agents. 2019; 54(5):562-571. DOI: 10.1016/j.ijantimicag.2019.06.025. View

Balouch M, Bajwa R, Hassoun A . Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother. 2014; 70(2):624-5. DOI: 10.1093/jac/dku392. View

Jackson T, Paraskevopoulos T, Georgalas I . Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014; 59(6):627-35. DOI: 10.1016/j.survophthal.2014.06.002. View

10.

Van Hal S, Jensen S, Vaska V, Espedido B, Paterson D, Gosbell I . Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012; 25(2):362-86. PMC: 3346297. DOI: 10.1128/CMR.05022-11. View

11.

Roujansky A, Martin M, Gomart C, Hulin A, Mounier R . Multidrug-Resistant Staphylococcus epidermidis Ventriculostomy-Related Infection Successfully Treated by Intravenous Ceftaroline after Failure of Daptomycin Treatment. World Neurosurg. 2020; 136:221-225. DOI: 10.1016/j.wneu.2020.01.013. View

12.

Tunkel A, Hasbun R, Bhimraj A, Byers K, Kaplan S, Scheld W . 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis. 2017; 64(6):e34-e65. PMC: 5848239. DOI: 10.1093/cid/ciw861. View

13.

Di Paolo A, Gori G, Tascini C, Danesi R, Del Tacca M . Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin Pharmacokinet. 2013; 52(7):511-42. DOI: 10.1007/s40262-013-0062-9. View

14.

Ho D, Clayton N, Silverstein B, Koff A . Endogenous Endophthalmitis From Methicillin-Resistant Staphylococcus aureus Bacteremia Treated With Ceftaroline. Cureus. 2022; 14(2):e22216. PMC: 8926881. DOI: 10.7759/cureus.22216. View

15.

Helfer V, Zavascki A, Zeitlinger M, Araujo B, Dalla Costa T . Population Pharmacokinetic Modeling and Probability of Target Attainment of Ceftaroline in Brain and Soft Tissues. Antimicrob Agents Chemother. 2022; 66(9):e0074122. PMC: 9487611. DOI: 10.1128/aac.00741-22. View

16.

Minejima E, Mai N, Bui N, Mert M, Mack W, She R . Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis. 2019; 70(4):566-573. PMC: 7768749. DOI: 10.1093/cid/ciz257. View

17.

Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R . Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52(3):e18-55. DOI: 10.1093/cid/ciq146. View

18.

Chauzy A, Nadji A, Combes J, Defrance N, Bouhemad B, Couet W . Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain. J Antimicrob Chemother. 2018; 74(3):675-681. DOI: 10.1093/jac/dky489. View